Analysts count on revenue increase Celgene

Tomorrow Celgene will publish its past quarter's results. Over the current book year the total revenue will be 15,17 billion USD (consensus estimates). This is rather significant more than 2017's revenue of 13 billion USD.

Historical revenues and results Celgene plus estimates 2018

The analysts expect for 2018 a net profit of 6,49 billion USD. For this year most of the analysts expect a profit per share of 8,76 USD. So the price/earnings-ratio equals 9,2.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is a limited 0,5 percent.

Newest target prices around 101 USD

Celgene 's market capitalization is around 62,76 billion USD. The Celgene stock was the past 12 months quite volatile. Since last October the stock is 34 percent lower. This year the stock price moved between 74 and 123 dollar. Since 2008 the stock price is almost 178 percent higher.

Historical stock prices Celgene

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.